OPZELURA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPZELURA (OPZELURA).
Topical Janus kinase (JAK) inhibitor; inhibits JAK1 and JAK2, leading to decreased STAT phosphorylation and modulation of inflammatory cytokine production.
| Metabolism | Hepatic metabolism primarily via CYP3A4 and CYP2C9. |
| Excretion | Approximately 70% of the dose is excreted in feces (as unchanged drug and metabolites), and approximately 30% is excreted in urine (as unchanged drug and metabolites). |
| Half-life | Approximately 4.9 hours (range 3.2–7.6 hours) in healthy subjects; clinical impact: supports twice-daily dosing. |
| Protein binding | Approximately 99.7% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Approximately 3.6 L/kg; indicates extensive extravascular distribution. |
| Bioavailability | Topical: Systemic absorption is minimal but measurable; bioavailability not applicable due to topical route; oral bioavailability (if ingested) is approximately 50% (not clinically relevant). |
| Onset of Action | Topical: Improvement in pruritus can be observed within 2 weeks; significant reduction in Eczema Area and Severity Index (EASI) scores by 4 weeks. |
| Duration of Action | Duration of action: 12 hours; with twice-daily application, clinical improvement is sustained; note: continuous use is required for maintenance. |
1.5% topical cream applied twice daily to affected areas; not for ophthalmic, oral, or intravaginal use.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (eGFR <30 mL/min). |
| Liver impairment | No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment; not recommended for severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients <12 years have not been established; for ≥12 years, same as adult dosing. |
| Geriatric use | No specific dose adjustment recommended; limited data in patients ≥65 years; use with caution due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPZELURA (OPZELURA).
| Breastfeeding | It is unknown whether ruxolitinib is excreted in human milk, but it is excreted in the milk of lactating rats. The M/P ratio is not available for humans. Due to the potential for serious adverse reactions in nursing infants from ruxolitinib, breastfeeding is not recommended during treatment and for 4 weeks after the last dose. |
| Teratogenic Risk | In animal studies, ruxolitinib (active ingredient of OPZELURA) was associated with increased post-implantation loss, reduced fetal body weight, and skeletal variations at systemic exposures comparable to the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Based on animal data, there is a potential risk to the fetus, including developmental toxicity. Use during pregnancy is not recommended unless the potential benefit justifies the potential risk to the fetus. Women of reproductive potential should be advised to use effective contraception during treatment and for at least 4 weeks after the last dose. |
■ FDA Black Box Warning
Increased risk of serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis with use of JAK inhibitors. However, a boxed warning specific to topical ruxolitinib may not be explicitly listed; the boxed warning for systemic JAK inhibitors is typically not included for topical forms, but the FDA label may include serious warnings.
| Serious Effects |
Tuberculosis or other serious infections; severe hepatic impairment; pregnancy; breastfeeding; known hypersensitivity to ruxolitinib or any component of the formulation.
| Precautions | Serious infections, including bacterial, fungal, viral, and opportunistic infections; malignancy; thrombosis; major adverse cardiovascular events; increase in lipid parameters; treatment discontinuation for serious adverse reactions; application site reactions; use in immunocompromised patients; use with other JAK inhibitors or potent immunosuppressants. |
Loading safety data…
| Fetal Monitoring | Monitor complete blood counts (CBC) with differential at baseline and periodically thereafter, as ruxolitinib can cause thrombocytopenia, anemia, and neutropenia. In pregnant women, monitor fetal growth and development with appropriate ultrasound examinations. Assess for signs of infection, as ruxolitinib may increase the risk of infections. |
| Fertility Effects | In animal studies, ruxolitinib did not impair male or female fertility at systemic exposures up to approximately 5.5 times the maximum human exposure. However, based on its mechanism of action (JAK inhibition), there is a theoretical potential for effects on reproductive tissues. Human fertility data are not available. |